{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:01:54Z","timestamp":1773288114646,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.bcp.2004.03.029","type":"journal-article","created":{"date-parts":[[2004,6,2]],"date-time":"2004-06-02T13:45:54Z","timestamp":1086183954000},"page":"341-350","source":"Crossref","is-referenced-by-count":52,"title":["Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells"],"prefix":"10.1016","volume":"68","author":[{"given":"Ellen","family":"Niederberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Manderscheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Gr\u00f6sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Ehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Geisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bcp.2004.03.029_BIB1","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors","volume":"44","author":"del Rincon","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.bcp.2004.03.029_BIB2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/art.10089","article-title":"Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?","volume":"46","author":"Van Doornum","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.bcp.2004.03.029_BIB3","first-page":"2562","article-title":"Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset","volume":"26","author":"Wallberg-Jonsson","year":"1999","journal-title":"J. Rheumatol."},{"issue":"21","key":"10.1016\/j.bcp.2004.03.029_BIB4","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1161\/01.CIR.100.21.2124","article-title":"A tale of two diseases: atherosclerosis and rheumatoid arthritis","volume":"100","author":"Pasceri","year":"1999","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2004.03.029_BIB5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00002281-200203000-00007","article-title":"Coronary artery disease and rheumatoid arthritis","volume":"142","author":"Goodson","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"issue":"6A","key":"10.1016\/j.bcp.2004.03.029_BIB6","doi-asserted-by":"crossref","first-page":"33D","DOI":"10.1016\/S0002-9149(02)02235-X","article-title":"Relative risk of cardiovascular events in patients with rheumatoid arthritis","volume":"89","author":"DeMaria","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"6460","key":"10.1016\/j.bcp.2004.03.029_BIB7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/367215a0","article-title":"Towards a better aspirin","volume":"367","author":"Vane","year":"1994","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.bcp.2004.03.029_BIB8","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1161\/01.CIR.102.17.2124","article-title":"Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1)","volume":"102","author":"Marra","year":"2000","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.bcp.2004.03.029_BIB9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0024-3205(00)00950-4","article-title":"The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice","volume":"68","author":"Paul","year":"2000","journal-title":"Life Sci."},{"issue":"21","key":"10.1016\/j.bcp.2004.03.029_BIB10","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2004.03.029_BIB11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bcp.2004.03.029_BIB12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.bcp.2004.03.029_BIB13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/ejvs.2000.1145","article-title":"Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries","volume":"20","author":"Stemme","year":"2000","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"4","key":"10.1016\/j.bcp.2004.03.029_BIB14","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0002-9440(10)65230-3","article-title":"Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions","volume":"155","author":"Schonbeck","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.bcp.2004.03.029_BIB15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0021-9150(73)90031-2","article-title":"Increased endothelial cell turnover in areas of in vivo Evans Blue uptake in the pig aorta","volume":"17","author":"Caplan","year":"1973","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.bcp.2004.03.029_BIB16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/01.CIR.98.1.82","article-title":"Cell cycle progression: new therapeutic target for vascular proliferative disease","volume":"98","author":"Braun-Dullaeus","year":"1998","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2004.03.029_BIB17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/(SICI)1099-081X(199909)20:6<293::AID-BDD188>3.0.CO;2-X","article-title":"Plasma protein binding of celecoxib in mice rat rabbit dog and human","volume":"20","author":"Paulson","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2004.03.029_BIB18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-4347(01)00333-4","article-title":"Determination of celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry","volume":"761","author":"Brautigam","year":"2001","journal-title":"J. Chromatogr B. Biomed. Sci. Appl."},{"issue":"9","key":"10.1016\/j.bcp.2004.03.029_BIB19","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1096\/fj.00-0716fje","article-title":"Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB","volume":"15","author":"Niederberger","year":"2001","journal-title":"FASEB J."},{"issue":"23","key":"10.1016\/j.bcp.2004.03.029_BIB20","doi-asserted-by":"crossref","first-page":"12764","DOI":"10.1073\/pnas.210394497","article-title":"Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice","volume":"97","author":"Reis","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.bcp.2004.03.029_BIB21","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1073\/pnas.061607398","article-title":"Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice","volume":"98","author":"Pratico","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"15","key":"10.1016\/j.bcp.2004.03.029_BIB22","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1161\/01.CIR.0000014927.74465.7F","article-title":"Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice","volume":"105","author":"Burleigh","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2004.03.029_BIB23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/01.CIR.0000051361.69808.3A","article-title":"Selective COX-2 inhibition improves endothelial function in coronary artery disease","volume":"107","author":"Chenevard","year":"2003","journal-title":"Circulation"},{"issue":"6A","key":"10.1016\/j.bcp.2004.03.029_BIB24","doi-asserted-by":"crossref","first-page":"26D","DOI":"10.1016\/S0002-9149(02)02234-8","article-title":"Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations","volume":"89","author":"FitzGerald","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"5 Pt 2","key":"10.1016\/j.bcp.2004.03.029_BIB25","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/S0002-8703(99)70266-8","article-title":"Atherosclerosis is an inflammatory disease","volume":"138","author":"Ross","year":"1999","journal-title":"Am. Heart J."},{"issue":"12","key":"10.1016\/j.bcp.2004.03.029_BIB26","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1002\/art.10692","article-title":"Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib but not by other selective cyclooxygenase 2 inhibitors","volume":"46","author":"Kusunoki","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.bcp.2004.03.029_BIB27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0014-5793(02)03535-4","article-title":"Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells","volume":"531","author":"Yamazaki","year":"2002","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.bcp.2004.03.029_BIB28","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1096\/fj.01-0390rev","article-title":"Cyclooxygenase-independent actions of cyclooxygenase inhibitors","volume":"15","author":"Tegeder","year":"2001","journal-title":"FASEB J."},{"issue":"26","key":"10.1016\/j.bcp.2004.03.029_BIB29","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib a cyclooxygenase-2 inhibitor in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2004.03.029_BIB30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor","volume":"38","author":"Davies","year":"2000","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.bcp.2004.03.029_BIB31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/hh2101.099268","article-title":"Cytochrome p450 and vascular homeostasis","volume":"89","author":"Fleming","year":"2001","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.bcp.2004.03.029_BIB32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1124\/jpet.102.044016","article-title":"Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation","volume":"304","author":"Niederberger","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295204002084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295204002084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T08:18:15Z","timestamp":1549613895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295204002084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0006295204002084"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2004.03.029","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}